Praxis Precision Medicines, Inc. (PRAX)
NASDAQ: PRAX · Real-Time Price · USD
341.75
-3.55 (-1.03%)
Sep 10, 2026, 1:20 PM EDT - Market open
PRAX Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
168
Market Cap
9.54B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 8.55M | 6.11M | 249.53% |
| Dec 31, 2023 | 2.45M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bio-Techne | 1.22B |
| Ionis Pharmaceuticals | 874.09M |
| Axsome Therapeutics | 776.57M |
| Krystal Biotech | 440.48M |
| Protagonist Therapeutics | 281.99M |
| ImmunityBio | 165.79M |
| Kymera Therapeutics | 105.00M |
| Cytokinetics | 67.67M |
PRAX News
- 6 days ago - Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 20 days ago - Praxis Precision price target raised to $575 from $470 at Goldman Sachs - TheFly
- 24 days ago - Praxis Precision price target raised to $945 from $765 at Raymond James - TheFly
- 4 weeks ago - Praxis Precision price target raised to $462 from $449 at RBC Capital - TheFly
- 4 weeks ago - Praxis Precision price target raised to $514 from $400 at Baird - TheFly
- 4 weeks ago - Praxis Precision price target raised to $362 from $323 at Wells Fargo - TheFly
- 5 weeks ago - Praxis Precision Medicines Earnings Call Transcript: Q2 2026 - Transcripts
- 5 weeks ago - Praxis Precision Medicines Earnings release: Q2 2026 - Filings